{"title":"对重组人Rh-内司他丁联合同期放疗治疗宫颈癌的疗效和安全性的回顾性分析。","authors":"Xin Zhang, Qian Li, Kuan Liu, Hong-Yun Shi","doi":"10.12669/pjms.40.8.8770","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Retrospective study and analysis of the safety and efficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer.</p><p><strong>Methods: </strong>A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Affiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent efficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side effects.</p><p><strong>Results: </strong>The difference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant(<i>P</i>>0.05), and the CR of the observation group was significantly higher than that of the control group(<i>P</i><0.05). The proportion of neutropenia, hypertension, arrhythmia, hemoglobin reduction in the observation group was significantly higher than that in the control group, and the proportion of nausea and vomiting was significantly lower than that in the control group(<i>P</i><0.05), and there was no significant difference in other adverse reactions(<i>P</i>>0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(<i>P</i><0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(<i>P</i><0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group(<i>P</i><0.05).</p><p><strong>Conclusions: </strong>Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.</p>","PeriodicalId":19958,"journal":{"name":"Pakistan Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11395371/pdf/","citationCount":"0","resultStr":"{\"title\":\"Retrospective analysis of efficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer.\",\"authors\":\"Xin Zhang, Qian Li, Kuan Liu, Hong-Yun Shi\",\"doi\":\"10.12669/pjms.40.8.8770\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Retrospective study and analysis of the safety and efficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer.</p><p><strong>Methods: </strong>A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Affiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent efficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side effects.</p><p><strong>Results: </strong>The difference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant(<i>P</i>>0.05), and the CR of the observation group was significantly higher than that of the control group(<i>P</i><0.05). The proportion of neutropenia, hypertension, arrhythmia, hemoglobin reduction in the observation group was significantly higher than that in the control group, and the proportion of nausea and vomiting was significantly lower than that in the control group(<i>P</i><0.05), and there was no significant difference in other adverse reactions(<i>P</i>>0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(<i>P</i><0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(<i>P</i><0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group(<i>P</i><0.05).</p><p><strong>Conclusions: </strong>Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.</p>\",\"PeriodicalId\":19958,\"journal\":{\"name\":\"Pakistan Journal of Medical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11395371/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan Journal of Medical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12669/pjms.40.8.8770\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12669/pjms.40.8.8770","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Retrospective analysis of efficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer.
Objective: Retrospective study and analysis of the safety and efficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer.
Methods: A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Affiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent efficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side effects.
Results: The difference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant(P>0.05), and the CR of the observation group was significantly higher than that of the control group(P<0.05). The proportion of neutropenia, hypertension, arrhythmia, hemoglobin reduction in the observation group was significantly higher than that in the control group, and the proportion of nausea and vomiting was significantly lower than that in the control group(P<0.05), and there was no significant difference in other adverse reactions(P>0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(P<0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(P<0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group(P<0.05).
Conclusions: Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.
期刊介绍：
It is a peer reviewed medical journal published regularly since 1984. It was previously known as quarterly "SPECIALIST" till December 31st 1999. It publishes original research articles, review articles, current practices, short communications & case reports. It attracts manuscripts not only from within Pakistan but also from over fifty countries from abroad.
Copies of PJMS are sent to all the import medical libraries all over Pakistan and overseas particularly in South East Asia and Asia Pacific besides WHO EMRO Region countries. Eminent members of the medical profession at home and abroad regularly contribute their write-ups, manuscripts in our publications. We pursue an independent editorial policy, which allows an opportunity to the healthcare professionals to express their views without any fear or favour. That is why many opinion makers among the medical and pharmaceutical profession use this publication to communicate their viewpoint.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
